Lucerastat, an iminosugar for substrate reduction therapy in Fabry Disease: Preclinical evidence

Lucerastat, an iminosugar for substrate reduction therapy in Fabry Disease: Preclinical evidence

Veure altres versions (1)

Fabry disease (FD) is a lysosomal storage disorder caused by mutations in the GLA gene coding for α-galactosidase A (α-GalA). These mutations lead to the accumulation of α-GalA substrates, including globotriaosylceramide (Gb3). As a consequence of lipid storage, Fabry patients can suffer from neurop...

Descripció completa

Dades bibliogràfiques
Autors principals:	Welford, R, Mühleman, A, Priestman, D, Garzotti, M, Deymier, C, Ertel, E, Iglarz, M, Morand, O, Platt, F, Probst, M
Format:	Conference item
Publicat:	Karger 2017

Ítems similars

Lucerastat, an iminosugar for substrate reduction therapy in Fabry disease: preclinical evidence
per: Priestman, D, et al.
Publicat: (2017)

Iminosugar inhibitors for treating the lysosomal glycosphingolipidoses
per: Butters, T, et al.
Publicat: (2005)

Severe endothelial dysfunction in the aorta of a mouse model of Fabry disease; partial prevention by N-butyldeoxynojirimycin treatment.
per: Heare, T, et al.
Publicat: (2007)

Imino sugar therapy for type 1 Gaucher disease.
per: Priestman, D, et al.
Publicat: (2000)

The effect of the glucosylceramide synthase inhibitor lucerastat on cardiac repolarization: results from a thorough QT study in healthy subjects
per: Markus S. Mueller, et al.
Publicat: (2020-10-01)

Reduced sphingolipid hydrolase activities, substrate accumulation and ganglioside decline in Parkinson’s disease
per: Huebecker, M, et al.
Publicat: (2019)

Assessment of Target Engagement in a First‐in‐Human Trial with Sinbaglustat, an Iminosugar to Treat Lysosomal Storage Disorders
per: Martine Gehin, et al.
Publicat: (2021-03-01)

Iminosugar for treatment of tumors
per: Dwek, R, et al.
Publicat: (2008)

Iminosugar antivirals: the therapeutic sweet spot
per: Alonzi, D, et al.
Publicat: (2017)

Substrate reduction therapy.
per: Platt, F, et al.
Publicat: (2008)

The mechanism of action of iminosugars as antiretrovirals
per: Spiro, S, et al.
Publicat: (2014)

The synthesis and biology of iminosugars and their precursors
per: Ayers, B, et al.
Publicat: (2014)

The synthesis of branched sugars and iminosugars
per: Parry, LL
Publicat: (2011)

Total asymmetric syntheses of iminosugars
per: Figuccia, A, et al.
Publicat: (2015)

Substrate reduction augments the efficacy of enzyme therapy in a mouse model of Fabry disease.
per: John Marshall, et al.
Publicat: (2010-11-01)

Brain pathology in mucopolysaccharidoses (MPS) patients with neurological forms
per: Viana, GM, et al.
Publicat: (2020)

The synthesis of azetidine and piperidine iminosugars from monosaccharides
per: Lenagh-Snow, G, et al.
Publicat: (2012)

Glycomimetic affinity-enrichment proteomics identifies partners for a clinically-utilized iminosugar
per: Cruz, I, et al.
Publicat: (2013)

Inhibition of pyruvate dehydrogenase kinase by pyruvate in cultured cardiac myocytes
per: Priestman, D, et al.
Publicat: (1997)

Reduced sphingolipid hydrolase activities, substrate accumulation and ganglioside decline in Parkinson’s disease
per: Mylene Huebecker, et al.
Publicat: (2019-11-01)

Substrate reduction therapy
per: Platt, F, et al.
Publicat: (2007)

Glycosphingolipid profiling of tissues from mouse models of human lysosomal storage disorders
per: Priestman, D, et al.
Publicat: (2008)

Increased glycosphingolipid levels in serum and aortae of apolipoprotein E gene knockout mice.
per: Garner, B, et al.
Publicat: (2002)

The apo E gene knockout mouse as a model to study the potential atherogenic properties of glycosphingolipids
per: Garner, B, et al.
Publicat: (2003)

Iminosugars and methods of treating Arenaviral infections
per: Ramstedt, U, et al.
Publicat: (2010)

Iminosugars and methods of treating viral diseases
per: Ramstedt, U, et al.
Publicat: (2011)

Iminosugars: promising therapeutics for influenza infection
per: Tyrrell, B, et al.
Publicat: (2016)

Iminosugars : from synthesis to therapeutic applications /
per: Compain, Philippe, et al.
Publicat: (2007)

Iminosugars and methods of treating Filoviral diseases
per: Ramstedt, U, et al.
Publicat: (2011)

Correction to: Reduced sphingolipid hydrolase activities, substrate accumulation and ganglioside decline in Parkinson’s disease
per: Mylene Huebecker, et al.
Publicat: (2020-01-01)

A Novel Iminosugar UV-12 with Activity against the Diverse Viruses Influenza and Dengue (Novel Iminosugar Antiviral for Influenza and Dengue)
per: Kelly L. Warfield, et al.
Publicat: (2015-05-01)

Development of a Biosimilar of Agalsidase Beta for the Treatment of Fabry Disease: Preclinical Evaluation
per: André B. P. van Kuilenburg, et al.
Publicat: (2023-04-01)

α-Glucosidase inhibition of lactone intermediates of the iminosugar deoxynojirimycin
per: Wai Haan, Y, et al.
Publicat: (2019)

N-butyldeoxynojirimycin causes weight loss as a result of appetite suppression in lean and obese mice.
per: Priestman, D, et al.
Publicat: (2008)

Rare monosaccharides and biologically active iminosugars from carbohydrate chirons
per: Best, D
Publicat: (2011)

Long alkylchain iminosugars block the HCV p7 ion channel
per: Pavlovic, D, et al.
Publicat: (2005)

Brain Pathology in Mucopolysaccharidoses (MPS) Patients with Neurological Forms
per: Viana, GM, et al.
Publicat: (2020)

Glycosphingolipid metabolism and its role in ageing and Parkinson’s disease
per: Wallom, K-L, et al.
Publicat: (2021)

Antiviral effects of an iminosugar derivative on flavivirus infections.
per: Wu, S, et al.
Publicat: (2002)

Iminosugars and methods of treating Bunyaviral and Togaviral diseases
per: Ramstedt, U, et al.
Publicat: (2010)